Rituximab for Pediatric Central Nervous System Inflammatory Disorders in Alberta, Canada.
Ihor PecuhJeremy SlobodanJennifer A McCombeFrancois-Dominique Morneau-JacobPenelope SmythColin WilburPublished in: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (2023)
The use of rituximab for pediatric CNS inflammatory disorders has increased, particularly for the indication of autoimmune encephalitis. This study identified significant heterogeneity in dosing practices and laboratory monitoring. Standardized protocols for the use of rituximab in these disorders and more robust outcome reporting will help better define the safety and efficacy of rituximab in this population.